Article Figures & Data
Figures
- FIGURE 1.
Chemical structure of 18F-BAY 864367.
- FIGURE 2.
Results from 63-y-old patient (patient 3). (A) Axial slice of CT image of pelvis. (B) Axial slice of fused PET/CT image of prostate, showing BAY 864367–positive PCa mainly in right apical lobe. (C) Corresponding histopathology slice with simultaneous staining of antibodies targeting cytokeratin 5 and 14, P63, and AMACR/P504S (mirrored horizontally).
- FIGURE 3.
Results from 64-y-old patient who showed biochemical failure 11 y after initial diagnosis and extended prostatectomy. (A) Maximum-intensity projection 90 min after injection of 306 MBq of BAY 864367 (with arrow marking lymph node). (B) Axial slice of fused PET/CT images, showing bombesin-positive lymph node (arrow) dorsal to right external iliac vein. (C and D) Maximum-intensity projection of diagnostic 18F-fluorocholine PET and fused choline PET/CT slice showing no choline uptake in iliac lymph node. Unit of scale bar is g/mL (SUV).
- FIGURE 4.
Maximum-intensity projection PET images of serial static PET series from 30 to 110 min after injection of 317 MBq of BAY 864367 (patient 10). All images are displayed at same level of intensity. No pathologic uptake of BAY 864367 is seen.
Tables
Patient no. Age (y) Diagnosis 18F-fluorocholine PET/CT–positive tumor lesions BAY 864367 PET/CT findings 1 67 PCa, ID 01/2010 — Tumor activity, left peripheral prostate (SUVmax, 2.4) 2 79 PCa, ID 04/2010 Suggestive of central PCa Suggestive of central PCa (SUVmax, 13.1) 3 63 PCa, ID 04/2010 Suggestive of PCa, apical right; no clear evidence of LN met Suggestive of PCa, apical right; no clear evidence of LN met (SUVmax, 11.8) 4 74 PCa, ID 07/2010 PCa bilaterally peripheral, no LN No focal radionuclide uptake 5 67 PCa, ID 07/2010 Suggestive of PCa, both lobes No focal radionuclide uptake 6 77 PCa, ID 01/2007; rP; prostate-specific antigen rec 06/2009 Local rec dorsal of left ureter (1.2 cm) (SUVmax early and late, 1.7) No focal radionuclide uptake 7 60 PCa, ID 11/1996; rP; prostate-specific antigen rec 08/2008 Local rec in prostate compartment (SUVmax early, 5.0; SUVmax late, 5.6) No focal radionuclide uptake 8 68 PCa, ID 09/2007; rP; prostate-specific antigen rec 01/2010 Osteosclerotic met in fourth rib, left side Minimal local osseous activity in left lateral fourth rib (SUVmax, 2.8) 9 64 PCa, ID 02/1999; rP Suggestive of bone met, th5 and th6 (which could not be proven on follow-up choline PET) Lesion dorsal to right external iliac vein below bifurcation, with maximal diameter of 11 mm (SUVmax, 13.2) 10 75 PCa, ID 2004, radiation therapy; prostate-specific antigen rec 09/2007 Multiple bone and LN met No focal radionuclide uptake ID = initial diagnosis; LN = lymph node; rP = radical prostatectomy; rec = recurrence; met = metastases; th = thoracic vertebra.
Uptake after 1.5 h Patient Gleason score Prostate-specific antigen (μg/L) BAY 864367 (MBq) Dose (mSv/patient) Lung (SUVmax) Tumor (SUVmax) Relative (tumor/lung) 1 9 16.2 308 4.40 0.5 2.4 4.8 2 8 24.3 282 3.69 0.8 13.1 16.4 3 9 19.4 287 4.53 0.7 11.8 16.9 4 7 13.9 315 4.32 0.8 — — 5 8 9.3 305 3.93 0.5 — — 6 9 5.47 300 4.56 0.7 — — 7 7 11.9 298 4.59 0.7 — — 8 9 3.58 298 4.14 0.6 2.8 4.7 9 8 16.7 306 4.90 0.6 13.2 22 10 9 214 317 4.06 0.4 — — Patient no. Lesion type Lesion size (cm) BAY 864367 18F-fluorocholine Confirmation 1 Primary tumor 2.3 + (TP) NA Prostatectomy Two local LNs 0.5 − (FN) NA Lymphadenectomy 2 Primary tumor 2.2 + (TP) + (TP) Biopsy 3 Primary tumor 2.1 + (TP) + (TP) Prostatectomy 4 Primary tumor 2.2 − (FN) + (TP) Prostatectomy 5 Primary tumor 1.5 − (FN) + (TP) Biopsy 6 Local recurrence 1.2 − (FN) + (TP) 18F-fluorocholine PET/CT 7 Local recurrence 1.4 − (FN) + (TP) 18F-fluorocholine PET/CT 8 Bone 0.9 + (TP) + (TP) 18F-fluorocholine PET/CT 9 Bone 1.2 − (TN) + (FP) Negative on follow-up LN 1.1 + (TP) − (FN) Persisting on follow-up 10 Multiple bone and LN 3.0 − (FN) + (TP) 18F-fluorocholine PET/CT TP = true-positive; NA = not applicable; LN = lymph node; FN = false-negative; FP = false-positive; TN = true-negative.
- TABLE 4
Absorbed Organ Dose (mGy/MBq) and Effective Dose (mSv/MBq) after Injection of 18F-BAY 864367
Organ Mean SD Minimum Maximum Adrenals 0.01354 0.00059363 0.0122 0.0143 Brain 0.01161 0.00073273 0.0106 0.0129 Breasts 0.009826 0.00037932 0.00922 0.0105 Gallbladder wall 0.03993 0.023838 0.016 0.0986 Lower large intestine wall 0.01431 0.00090824 0.0132 0.0158 Small intestine 0.01497 0.000564 0.0143 0.0162 Stomach wall 0.01326 0.00034117 0.0127 0.0138 Upper large intestine wall 0.01472 0.00048539 0.014 0.0158 Heart wall 0.01338 0.0003995 0.0127 0.0139 Kidneys 0.01656 0.00294931 0.0111 0.0211 Liver 0.022106 0.00778994 0.00606 0.0321 Lungs 0.00964 0.00155551 0.00705 0.012 Muscle 0.0084 0.00071663 0.00709 0.00938 Ovaries 0.01459 0.00079303 0.0136 0.0159 Pancreas 0.01436 0.00055172 0.0132 0.0153 Red marrow 0.01152 0.00067052 0.0109 0.0133 Osteogenic cells 0.01759 0.00079051 0.0165 0.019 Skin 0.008629 0.00030287 0.00822 0.00918 Spleen 0.01011 0.00166418 0.00752 0.0122 Testes 0.01145 0.00070887 0.0105 0.0125 Thymus 0.01134 0.00029052 0.0109 0.0119 Thyroid 0.01116 0.00034409 0.0107 0.0118 Urinary bladder wall 0.0499 0.02448567 0.0216 0.0944 Prostate 0.01606 0.00165421 0.014 0.0189 Total body 0.01204 0.00020591 0.0115 0.0122 Effective dose 0.01431 0.00115451 0.0128 0.016
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- Will GRPR Compete with PSMA as a Target in Prostate Cancer?
- Bombesin-Targeted PET of Prostate Cancer
- Radiopeptides for Imaging and Therapy: A Radiant Future